Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.

Kittipibul V, Mentz RJ, Young R, Butler J, Ezekowitz JA, Lam CSP, Ponikowski P, Voors A, Corda S, McMullan C, O'Connor CM, Anstrom KJ, Armstrong PW, VICTORIA Study Group

Open source

DOI: 10.1002/ehf2.15134
Published: 2025 Apr
Container: ESC heart failure
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ehf2.15134,
  title = {Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.},
  author = {Kittipibul V and Mentz RJ and Young R and Butler J and Ezekowitz JA and Lam CSP and Ponikowski P and Voors A and Corda S and McMullan C and O'Connor CM and Anstrom KJ and Armstrong PW and VICTORIA Study Group},
  year = {2025},
  journal = {ESC heart failure},
  doi = {10.1002/ehf2.15134},
  url = {https://doi.org/10.1002/ehf2.15134}
}

RIS

TY  - JOUR
TI  - Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.
AU  - Kittipibul V
AU  - Mentz RJ
AU  - Young R
AU  - Butler J
AU  - Ezekowitz JA
AU  - Lam CSP
AU  - Ponikowski P
AU  - Voors A
AU  - Corda S
AU  - McMullan C
AU  - O'Connor CM
AU  - Anstrom KJ
AU  - Armstrong PW
AU  - VICTORIA Study Group
PY  - 2025
JO  - ESC heart failure
DO  - 10.1002/ehf2.15134
UR  - https://doi.org/10.1002/ehf2.15134
ER  -

APA

V, K., RJ, M., R, Y., J, B., JA, E., CSP, L., P, P., A, V., S, C., C, M., CM, O., KJ, A., PW, A., & Group, V. S. (2025). Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.. ESC heart failure. https://doi.org/10.1002/ehf2.15134

Source records

pubmed · retrieved 2026-09-26T16:42:28.206Z